FDA Approves BioGaia's Request for Orphan Drug Designation

Published: Aug 06, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. BioGaia is in a very early stage of investigating the possibilities of developing a drug within this field and has submitted a request for orphan drug designation in the USA. The FDA Office of Orphan Product Development has now approved BioGaia’s request.

Help employers find you! Check out all the jobs and post your resume.

Back to news